← Leaderboards
Meghan Free
Univ Of North Carolina Chapel Hill
$843,045
Attributed
$3,372,181
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $682.7K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,372,181 · 1
By mechanism
R01$3,372,181 · 1
Top collaborators
- Dominic J Ciavatta5 shared
- Ronald J Falk5 shared
- Charles Jennette5 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Charles Jennette$2,659,979
- Dominic J Ciavatta$2,618,471
- Toni Darville$28,754,279
- Erin C Garcia$2,310,570
- Jenny P.y. Ting$81,674,016
Others in their field
Other Emerging Leaders on “Chimeric Antigen Receptor T Cells”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$21,497,910
- Crystal Mackall · Children'S Hosp Of Philadelphia$19,988,621
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- William H. Peranteau · Children'S Hosp Of Philadelphia$8,763,204
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$7,776,394
- Kole T Roybal · J. David Gladstone Institutes$7,404,890
Research focus
Chimeric Antigen Receptor T CellsAnimal ModelAgammaglobulinaemia Tyrosine KinaseAdaptive Immune SystemAutoantibodiesAutoantigensAntibodiesAutoimmune DiseasesAutoimmune ProcessAntineutrophil Cytoplasmic AntibodiesAutoimmunityAutoreactive B CellBeta-ChemokinesBiologyB-LymphocytesB-Lymphocyte SubsetsCell Adhesion MoleculesCellsCell TherapyCellular EngineeringCellular TargetingAutoimmune ResponsesChemokine ReceptorClinical Trials
Grant awards (5)
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$653,602
R01 · FY2024 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$682,709
R01 · FY2023 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$679,218
R01 · FY2022 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$677,829
R01 · FY2021 · DK
Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies$678,823
R01 · FY2020 · DK